Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Hexarelin
Examorelin, His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
A selective growth hormone secretagogue that stimulates GH release with minimal effects on cortisol and prolactin. Considered one of the 'cleanest' GH-releasing peptides due to its selectivity.
A synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides known. Stimulates GH release more strongly than most other GHS peptides, but also has significant effects on cortisol and prolactin.
Binds to ghrelin receptors (GHS-R) in the pituitary gland, triggering pulsatile growth hormone release. Unlike other GH secretagogues, it does not significantly increase cortisol, ACTH, or prolactin levels.
Binds to ghrelin receptors (GHS-R1a) in the pituitary and hypothalamus, triggering strong GH release. Also has direct cardioprotective effects independent of GH, including protection against ischemia-reperfusion injury. Activates the CD36 receptor in cardiac tissue.
- Growth hormone optimization
- Improved sleep quality
- Fat loss
- Muscle recovery and growth
- Anti-aging protocols
- Growth hormone optimization
- Muscle mass and strength
- Fat loss
- Cardiac protection (emerging research)
- Recovery from injury
- Headaches
- Water retention
- Tingling sensations
- Limited long-term human data
- May affect blood sugar
- Significant cortisol and prolactin elevation (more than Ipamorelin)
- Water retention
- Increased appetite
- Desensitization with prolonged use
- Limited long-term human safety data
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Available through licensed 503A compounding pharmacies with a physician prescription.
- Ipamorelin, a new growth-hormone-releasing peptide
1998 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.